Alan Fishman

Analyst Alan Fishman of Thomas Weisel maintains his "overweight" rating on HealthSouth Corporation (NYSE: HLS). The target price for HLS is set to $23. According to Thomas Weisel, HealthSouth has reported its Q4 results inline with the estimates and the guidance reflecting strong operating...